177 related articles for article (PubMed ID: 32847326)
21. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Robertson L; Yeoh SE; Ramli A
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
[TBL] [Abstract][Full Text] [Related]
22. Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.
Grymonprez M; Vanspranghe K; Steurbaut S; De Backer TL; Lahousse L
Cardiovasc Drugs Ther; 2023 Aug; 37(4):781-791. PubMed ID: 34637052
[TBL] [Abstract][Full Text] [Related]
23. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
[TBL] [Abstract][Full Text] [Related]
24. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
25. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation – meta-analysis.
Senoo K; Lau YC; Dzeshka M; Lane D; Okumura K; Lip GY
Circ J; 2015; 79(2):339-45. PubMed ID: 25501801
[TBL] [Abstract][Full Text] [Related]
28. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
De Caterina R; John Camm A
Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
[TBL] [Abstract][Full Text] [Related]
29. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
[TBL] [Abstract][Full Text] [Related]
31. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
[TBL] [Abstract][Full Text] [Related]
32. Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis.
Caldeira D; Costa J; Ferreira JJ; Lip GY; Pinto FJ
Clin Res Cardiol; 2015 Jul; 104(7):582-90. PubMed ID: 25643952
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
[TBL] [Abstract][Full Text] [Related]
34. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.
Harel Z; Sholzberg M; Shah PS; Pavenski K; Harel S; Wald R; Bell CM; Perl J
J Am Soc Nephrol; 2014 Mar; 25(3):431-42. PubMed ID: 24385595
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.
Makam RCP; Hoaglin DC; McManus DD; Wang V; Gore JM; Spencer FA; Pradhan R; Tran H; Yu H; Goldberg RJ
PLoS One; 2018; 13(5):e0197583. PubMed ID: 29795629
[TBL] [Abstract][Full Text] [Related]
36. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Barba M; Yosuico VED; Terrenato I; Sperati F; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006466. PubMed ID: 29285754
[TBL] [Abstract][Full Text] [Related]
37. Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants.
Caldeira D; Barra M; Ferreira A; Rocha A; Augusto A; Pinto FJ; Costa J; Ferreira JJ
Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1239-49. PubMed ID: 26434935
[TBL] [Abstract][Full Text] [Related]
38. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
[No Abstract] [Full Text] [Related]
39. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Senoo K; Lip GY
Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
[TBL] [Abstract][Full Text] [Related]
40. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]